Follistatin is a protein your body already makes. It binds and neutralizes several members of the TGF-beta family, including activin and the muscle-limiting factor myostatin (also called GDF-8). By soaking up those signals, follistatin removes a brake on muscle growth. That single fact is why it draws so much attention from the muscle-building corner of the peptide market, and why it sits on the WADA Prohibited List.
A quick word on what it is not. Follistatin is not a short synthetic peptide like BPC-157 or a GLP-1 drug. It is a full secreted glycoprotein, and most of the serious research has tried to deliver it not as an injection of the protein but as a gene, using a virus to make muscle cells produce it locally.
How it works
Myostatin is a TGF-beta family signal that normally limits how big skeletal muscle gets. Animals lacking myostatin carry roughly twice the muscle mass. Follistatin is one of the most potent natural antagonists of that pathway. Structural studies show two follistatin molecules wrapping around a single activin ligand, burying about a third of its surface and blocking both its type I and type II receptor binding sites (Thompson et al., *Developmental Cell*, 2005; Harrington et al., *EMBO Journal*, 2006). Because follistatin also acts on pathways beyond myostatin alone, it can drive muscle growth through more than one route.
The clinical evidence
The most cited human work is a Phase 1/2a gene-therapy trial run at Nationwide Children's Hospital in patients with Becker muscular dystrophy. Researchers used the alternatively spliced FS344 variant, packaged in an AAV1 vector (AAV1.CMV.FS344), delivered by direct bilateral injection into the quadriceps. Six patients were dosed across two cohorts at 3 x 10^11 and 6 x 10^11 vg/kg per leg (Mendell et al., *Molecular Therapy*, 2015).
Results were mixed but real. On the 6-minute walk test, some patients gained meaningful distance (one improved 125 meters, another 108 meters), while others showed no change. Muscle biopsies in responders showed larger fiber size and reduced fibrosis. The authors reported no adverse effects over follow-up. It was described as the first gene-therapy trial to show functional improvement in a muscular dystrophy. The same approach was also studied in sporadic inclusion body myositis (NCT01519349).
Note what this evidence is and isn't. It comes from small, early-phase trials of a gene therapy delivered under medical supervision. It is not evidence that injecting follistatin protein bought online builds muscle or is safe.
Regulatory and anti-doping status
No follistatin product is approved as a drug by the FDA or other major regulators. Follistatin appears on the WADA Prohibited List under S4 (hormone and metabolic modulators) as an agent affecting myostatin function, and AAV-delivered follistatin falls under the gene and cell doping rules. WADA has funded work specifically on detecting follistatin doping in blood and urine.
The quality problem for anything sold online
This is where buyers should pay attention. A 2019 analysis tested 17 black-market "follistatin 344" products. Only nine actually contained follistatin. Several of the rest contained other growth-promoting peptides such as MGF and GHRP-2 instead. The nine genuine ones carried a His-tag and a lot of protein oligomers, markers of a crude recombinant product rather than anything resembling a controlled pharmaceutical (Walpurgis et al., *Drug Testing and Analysis*, 2019). In plain terms, more than half the tested vials were mislabeled, and even the "real" ones were not clean.
That finding is the reason a third-party COA matters. For a product like this, identity testing (is it actually follistatin?), purity, and mass-spec confirmation are not optional extras. peptideone aggregates independent testing signals and vendor COAs precisely so this kind of mislabeling is visible before purchase.
Follistatin sold as a research chemical is for laboratory research only and is not approved for human consumption. Nothing here is medical or dosing advice.